Sentences with phrase «new diabetes drugs»

JNJ is also working on a new diabetes drug which could push the stock to higher levels.

«New diabetes drug may help people with obesity lose weight.»

A new diabetes drug being developed by Bristol - Myers Squibb and AstraZeneca could be derailed by increased risks of bladder cancer and breast cancer.

Not only because Intarcia will have market adoption data, but also because a new diabetes drug launch typically costs somewhere between $ 225 million and $ 300 million.

JNJ is also working on a new diabetes drug which could push the stock to higher levels.

As we discuss on our website, Invokana is a relatively new diabetes drug manufactured by Johnson & Johnson.

Not exact matches

In a new study based on mice, scientists at Lancaster University found that a drug that goes after three diabetes - related targets «significantly reversed the memory deficit» in mice who got the drug, as measured by their performance in a maze test when compared to mice who didn't get the drug.

But what's worth noting is that somebody set out in this case not just to make a new drug but to solve a problem that often consumes the lives of diabetes patients.

Add one more name to the new slew of pharma companies trying to counteract the public backlash to big drug price increases: France's Sanofi, a $ 126 billion firm known for its flagship diabetes and vaccines units.

April 24 U.S. drugmaker Eli Lilly and Co reported a quarterly profit on Tuesday on higher demand for its newer treatments such as its diabetes drug Trulicity and psoriasis medicine Taltz.

Without it, Lilly is counting on other fresh market entries to pick up the slack, including diabetes drug Jardiance and Basaglar, its new biosimilar version of Sanofi's insulin blockbuster Lantus.

«The safety of low - kilojoule sweeteners is supported by regulatory agencies throughout the world, such as the The National Health and Medical Research Council, Food Standards Australia and New Zealand (FSANZ), European Food Safety Authority and the U.S. Food and Drug Administration, as well as leading health groups, including the Australian Diabetes Council and Dietitians Association of Australia.

«The safety of low - kilojoule sweeteners used in diet drinks is supported by leading regulatory agencies throughout the world, such as the U.S. Food and Drug Administration, the European Food Safety Authority, the National Health and Medical Research Council, and Food Standards Australia and New Zealand — as well as leading health groups, including the Australian Diabetes Council and Dieticians Association of Australia.»

A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of «good» cholesterol, despite being treated with statins.

In the new work, published June 10 in the journal Scientific Reports, Zhao, Reid and colleagues used a highly sensitive probe to measure electrical fields in the corneas of isolated eyes from three different lab mouse models with different types of diabetes: genetic, drug - induced and in mice fed a high - fat diet.

Manufacturing small proteins known as peptides is usually very time - consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.

«This could lead to a new therapeutic strategy for treating type 2 diabetes,» says Stanford, whose team believes that the drug could lead to fewer people with adult - onset diabetes becoming dependent on insulin injections.

Identifying the chemicals and networks that catalyze remission in type 2 diabetes would be a far more transformative advance, since it would help lead pharmaceutical companies toward new anti-diabetes drugs.

In some 3000 elderly people, Nir Barzilai of the Albert Einstein School of Medicine in the Bronx, New York, and his colleagues plan to conduct a trial in which half the subjects would get a placebo and half would get an old (indeed, ancient) drug for type 2 diabetes called metformin, which has been shown to modify aging in some animal studies.

Nondiabetic obese and overweight people lose more weight, are more likely to reverse prediabetes and are slower to develop type 2 diabetes when they take the diabetes drug liraglutide in addition to dieting and exercising, a new study finds.

Whereas most conventional scientists focus on a single system or disease, Butte earned tenure recently with a dossier of advances in diabetes, obesity, and transplant rejection, and the discovery of new drugs for lung cancer and other diseases.

Now, a new study adds another twist to the story: It argues that two commonly prescribed diabetes drugs with antioxidant properties also spur metastasis, at least in cancer cells and mice.

The good news is that there are a number of new drugs available right now which we are testing to see if they would reverse both Alzheimer's and diabetes symptoms.

Drugs used to treat diabetes could also be used to treat Alzheimer's disease, and vice versa, according to new research from the University of Aberdeen.

This research leads to new ideas for making drugs that, for example switch off immune activity in auto - immune diseases like diabetes or increasing immune reactivity to cancer.

Most of the new wave of drugs in development act to block the actions of specific proteins that bring on symptoms of diabetes, or they work to reduce obesity by dissolving fat or controlling appetite.

The frequency and growth of diabetes has not gone unnoticed by pharmaceutical companies — at least 20 firms are feverishly searching for remedies, and at least 40 new drugs are being tested.

In addition to illuminating how the drug, amlexanox, reverses obesity, diabetes and fatty liver disease, the findings suggest a new pathway for future treatments.

This group's achievement will lead to the clarification of the mechanism behind the localization of GLUT4 and the mechanism for developing diabetes, as well as the development of new types of treatment drugs.

As a consequence, new obesity and diabetes drugs that activate brown adipose tissue are expected to be more effective.

«New drug candidate could treat both type 2 diabetes, bone loss.»

Indeed, their combined phenotypic screening and target - identification approach enabled them to quickly discover, characterize and carry out preclinical tests of a potential new drug for obesity - linked diabetes: a complex metabolic disorder that affects 347 million people worldwide.

New research published in The Lancet has shown that a drug, currently used in the treatment of Type II diabetes, can be effective in clearing fatty liver disease from some patients.

The result is a new dual - targeting drug candidate — or, as Griffin describes, «one drug addressing multiple therapeutic indications» — that could treat both diabetes and bone disease.

One - third of adults in the United States are obese, so regulators must balance the risks of a new weight - loss drug with the health consequences of obesity, including rising diabetes rates.

Medical options also have improved substantially, with the availability in recent years of new classes of diabetes drugs such as GLP - 1 (glucagon - like peptide - 1) receptor agonists and SGLT2 (sodium - glucose co-transporter-2) inhibitors.

The cholesterol - lowering drug fenofibrate cuts cardiovascular disease risks by 30 per cent in women with type - 2 diabetes, a new University of Sydney study reveals.

The findings open up new avenues of research into exactly how the brain controls eating, and suggest that drugs designed to activate or inhibit neurons in the DRN could be effective in treating obesity and preventing its related disorders, such as diabetes and hypertension.

The results, which are published in the journal Cell Metabolism, can ultimately give rise to new obesity and diabetes drugs.

The finding, published in the journal Developmental Cell, opens up new possibilities for the development of drugs that block MCRS1 to treat cancer and diabetes.

6 - dependent protein, potentially opening avenues for new antibiotics and drugs to battle diseases such as drug - resistant tuberculosis, malaria and diabetes.

Now researchers report in tomorrow's Science a major new target for a drug to treat type 2 diabetes — and possibly for anti-obesity drugs as well.

Publication of the Diabetes Update coincided with the recent approval from the US Food and Drug Administration of a new dapagliflozin from AstraZeneca and Bristol - Myers Squibb for the treatment of adults with type 2 dDiabetes Update coincided with the recent approval from the US Food and Drug Administration of a new dapagliflozin from AstraZeneca and Bristol - Myers Squibb for the treatment of adults with type 2 diabetesdiabetes.

His research team is working to develop new bacterial - based drugs to lower blood glucose and combat prediabetes before type 2 diabetes develops.

MONDAY, July 15 (HealthDay News)-- The diabetes drug metformin may do more than help control blood sugar levels: New research suggests it may also reduce the risk of dementia.

If the 9th - century recipe does lead to new drugs, they might be useful against MRSA skin infections such as those that cause foot ulcers in people with diabetes.

«Alterations of metabolism in general are key to diabetes, and studies like this may have huge potential for unraveling new pathways which will lead to developing new drugs and new diagnostic tests,» she adds.

our stroke research, we will soon be able to find a gene within the type 2 diabetes locus we have identified and use this gene to identify powerful new drug targets.»

His research activity has been entirely devoted to diabetes, with focus on prediction and prevention of type 1 diabetes, new drugs for type 2 diabetes, innovative technologies for blood glucose monitoring.

Now, in a new study in the journal Cancer Cell, Shaw and a team of scientists at the Salk Institute for Biological Studies found that phenformin, a derivative of the widely - used diabetes drug metformin, decreased the size of lung tumors in mice and increased the animals» survival.